Peptide Comparisons
Side-by-side analysis of similar peptides based on published research
GLP-1 Receptor Agonists
Compare Semaglutide, Tirzepatide, and Retatrutide - the leading incretin-based peptides for metabolic research.
SemaglutideFDA Approved
Key Benefits
- •Longest clinical track record
- •Oral formulation available (Rybelsus)
- •Cardiovascular benefits proven
- •Weekly dosing convenience
Common Side Effects
- •Nausea (most common)
- •Vomiting
- •Diarrhea
- •Constipation
Key References
- Wilding JPH, et al. STEP 1 Trial. NEJM. 2021;384(11):989-1002
- Marso SP, et al. SUSTAIN-6 Trial. NEJM. 2016;375(19):1834-44
TirzepatideFDA Approved
Key Benefits
- •Greater weight loss than semaglutide
- •Dual receptor activation
- •Superior A1c reduction
- •Improved insulin sensitivity
Common Side Effects
- •Nausea
- •Diarrhea
- •Decreased appetite
- •Vomiting
Key References
- Jastreboff AM, et al. SURMOUNT-1 Trial. NEJM. 2022;387(3):205-16
- Frías JP, et al. SURPASS-2 Trial. NEJM. 2021;385(6):503-15
RetatrutideInvestigational
Key Benefits
- •Highest weight loss in trials
- •Triple receptor mechanism
- •Enhanced energy expenditure
- •Potential liver fat reduction
Common Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
Key References
- Jastreboff AM, et al. Retatrutide Phase 2. NEJM. 2023;389(6):514-26
- Rosenstock J, et al. Retatrutide in T2DM. Lancet. 2023;402(10401):529-44
Disclaimer: This comparison is for educational and research purposes only. Data is derived from published clinical trials and scientific literature. Individual responses may vary. Not intended to diagnose, treat, cure, or prevent any disease. Consult healthcare providers for medical decisions.